GC

CBD drug Epidiolex received approval from the U.S. Food and Drug Administration to deal with seizures related to a 3rd medical condition, increasing the vary of indications for the cannabis-derived treatment. Reports Hemp Industry Daily

The orally administered drug from Britain’s GW Pharmaceuticals beforehand was approved by the FDA to deal with seizures related to two types of extreme epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.

The new FDA approval, granted July 31 to GW’s U.S. subsidiary, Greenwich Biosciences, means the drug can now be used within the United States to deal with seizures related to tuberous sclerosis complicated, a genetic illness believed to have an effect on one in 6,000 individuals.

Full story at. https://hempindustrydaily.com/fda-approves-gw-pharmaceuticals-cbd-drug-for-new-indication/?utm_medium=email&utm_source=newsletter&utm_campaign=HEMP_20200804_Daily&elqTrackId=BBD7264BE82DA0B9617E5F52303FFDD0&elq=ecbaa76fdaa0404db94caa1290c5173b&elqaid=3828&elqat=1&elqCampaignId=2734

See the best guide for how to grow weed fast the dankest pot on Earth for beginners or advanced tips and tricks for growing marijuana.

Source link

Cannabis Products Training for Budtenders

LEAVE A REPLY

Please enter your comment!
Please enter your name here